source
- An eye drug biotech banks $118M and stocks its executive suiteClaris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for a blinding condition called limbal stem cell deficiency.
- The FDA was all in on AI. Will that change?High-level turnover has introduced uncertainty about how quickly the FDA’s agency-wide AI strategy will move forward.